Acquiring Company
GSK plc
Acquired Company
Nuvalent
CambridgeManufacturingBiotechnologyHealth CarePharmaceuticalBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalDescription
GSK has announced its agreement to acquire Nuvalent for $10.6 billion to enhance its oncology pipeline. This acquisition aims to leverage Nuvalent's innovative cancer therapies and research capabilities. The move underscores GSK's commitment to expanding its portfolio in the oncology field. The transaction is expected to position GSK more favorably within the competitive biopharmaceutical landscape.
Quick answer
GSK plc is acquiring Nuvalent for $10.6 billion, announced June 9, 2026.
- How much did GSK plc pay for Nuvalent?
- The reported deal value is $10.6 billion.
- What does GSK plc do?
- GSK plc is a global healthcare company that researches and develops innovative pharmaceutical products, including vaccines.
- Where are GSK plc and Nuvalent based?
- Nuvalent is based in Cambridge, Massachusetts, United States.
- Who are the decision-makers at GSK plc?
- Fundz holds 4 contacts at GSK plc. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Pharmaceutical and Healthcare
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Tarsus acquires iRenix Medical for IRX-101 development (July 8, 2026)
- ESTEVE acquires TerSera's Infusion Business Unit (May 4, 2026)
- Vertex to acquire Crinetics Pharmaceuticals for $10B, $10B (July 6, 2026)
- Bora Pharmaceuticals acquires MacroGenics' operations (July 2, 2026)
- Galmed Pharmaceuticals to acquire Colospan for GI focus (June 8, 2026)
- Gilead Sciences to acquire MacroGenics for $1.7B, $1.7B (May 19, 2026)
Who to call at GSK plc, and when
When GSK plc changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day GSK plc raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at GSK plc, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at GSK plc. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment GSK plc makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Nuvalent?
Nuvalent was acquired by GSK plc. The deal was reported on June 9, 2026. GSK plc is a global healthcare company that researches and develops innovative pharmaceutical products, including vaccines. GSK plc is publicly traded (GSK) and operates in Manufacturing.
When did GSK plc acquire Nuvalent?
GSK plc's acquisition of Nuvalent was reported on June 9, 2026. GSK has announced its agreement to acquire Nuvalent for $10.6 billion to enhance its oncology pipeline. This acquisition aims to leverage Nuvalent's innovative cancer therapies and research capabilities. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Nuvalent do?
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. The company aims to overcome the limitations of existing therapies for clinically proven kinase targets. It is privately held, operating in Biotechnology, and is based in Cambridge.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.